Recombinant glycoprotein vaccine

This page covers all Recombinant glycoprotein vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting RSV fusion (F) glycoprotein, prefusion conformation.

Targets

RSV fusion (F) glycoprotein, prefusion conformation

Marketed (1)

• AREXVY, ABRYSVO · National Heart, Lung, and Blood Institute (NHLBI) · Immunology / Infectious Disease
  AREXVY and ABRYSVO are recombinant glycoprotein F (RSVpreF3) vaccines that elicit immune responses against respiratory syncytial virus (RSV) to prevent RSV disease.

Patent intelligence

• recombinant glycoprotein vaccine patent landscape — aggregated cliff calendar, attackable patents, originator estates